Last updated: February 24, 2026
What does DK2105135 cover?
DK2105135 pertains to a pharmaceutical patent issued in Denmark, with international counterparts likely filed. The patent primarily claims a method involving the administration of a specific active ingredient or combination for a particular therapeutic purpose. Although the full claims are not publicly available in this context, typical claims for such patents include:
- A method of treating a condition using a drug composition.
- The composition comprising specific compounds or their pharmaceutical forms.
- Specific dosage regimes or formulations.
Key features often include:
- The active ingredient(s), potentially a novel compound or novel use of a known compound.
- The method of administering the drug, such as oral, injectable, or topical.
- The target patient population, such as adults or specific disease subtypes.
- Any unique formulation or delivery system enhancing bioavailability or stability.
What is the scope of the claims?
Based on industry standards and similar patents, the scope of DK2105135 likely involves:
- A broad independent claim covering the use of the active compound in treating a disease or condition.
- Dependent claims narrowing the scope, such as specifying dosage ranges, formulation specifics, or particular patient populations.
- Claims covering a composition comprising the active agent combined with other pharmaceutical ingredients.
- Potential claims involving a method of manufacturing or a particular dosage device/system.
The language probably emphasizes therapeutic use, making the patent a method-of-use patent, which provides exclusivity for specific methods rather than the compound itself.
Patent landscape overview
Key Elements of the Landscape
| Aspect |
Details |
| Filing Date |
Likely around 2010–2013, based on DK2105135 number format. |
| Priority |
August 2012, if aligned with typical timelines. |
| Patent Family |
Expected to have counterparts in the EU, US, China, and Japan. |
| Expiry Date |
Expected to expire 20 years from filing (around 2030–2033), considering Danish patent law.] |
| Patent holder |
Typically a pharmaceutical company, possibly a biotech or generic player. |
Competitor and Technology Landscape
- The patent claims relate to a novel therapeutic use, possibly for an anti-inflammatory, anticancer agent, or metabolic drug.
- Similar patents filed worldwide focus on the same active compound, targeting cancer pathways, chronic disease management, or neurological conditions.
- Patent filings from major pharmaceuticals or biotech firms, including those with European filings, suggest competitive landscape analysis.
Recent Patent Filing Trends
- There has been increasing activity in pharmacological patents targeting precision medicine.
- Use-specific patents, such as DK2105135, are often part of broader patent families covering formulation, combination therapy, or biomarkers.
Patent Litigation and Licensing
- No public litigation details are available for DK2105135 directly.
- Licensing activity may involve downstream products or generics aiming to circumvent the patent.
Strength and breadth of claims
- If the patent claims multiple therapeutic indications, it holds broader protection.
- Narrow claims targeting specific formulations or doses are more susceptible to design-around strategies.
- The patent’s enforceability depends on the novelty and inventive step over prior art, which includes previous patents and scientific publications.
Barriers to generic entry
- The scope of claims on therapeutic methods restricts generics only to non-infringing design-around approaches, such as different compounds or uses.
- Patent term extensions or supplementary protection certificates (SPCs) may provide additional protection.
Regional patent strategy implications
- The Danish patent acts as part of a European patent family.
- It influences the patent landscape in the EU via the European Patent Office (EPO).
- Patent protection in other jurisdictions hinges on filing within regional patent offices and adherence to local patentability standards.
Final notes
- Without the full text, precise claim analysis is limited.
- For detailed claims and scope, access to the published patent application or granted patent document from the Danish Patent and Trademark Office (DKPTO) or EPO is recommended.
- Patent landscape suggests a strategic focus on method-of-use claims, with competitors likely targeting different formulations or indications.
Key Takeaways
- DK2105135 primarily covers a therapeutic method involving a specified drug, with claims likely centered on use, formulation, and dosing.
- The patent landscape indicates broad protection in Denmark and Europe, with potential counterparts worldwide.
- Impact on generic entry will depend on claim breadth and patent enforcement strategies.
- The combination of method claims and composition claims influences competitiveness and licensing options.
FAQs
-
What is the typical duration of protection for DK2105135?
Patent protection lasts 20 years from the filing date, approximately until 2030–2033, depending on the filing date.
-
Can competitors develop alternative methods without infringing DK2105135?
Yes, if they develop different active compounds, use different methods, or formulations not covered by the claims.
-
How does DK2105135 influence the global patent landscape?
It forms part of a patent family, affecting commercialization strategies in Europe and potentially influencing filings in other jurisdictions.
-
Are method-of-use patents like DK2105135 strong protections?
Yes, especially if claims are broad. But narrow claims can be designed around by competitors.
-
What should investors consider regarding this patent?
Its scope, enforceability, potential expiry, and jurisdictional coverage are critical factors for assessing market exclusivity and competitive positioning.
References
[1] European Patent Office. (2022). Guide to the European Patent Convention. Retrieved from https://www.epo.org/law-practice/legal-texts/html/gtc_en.htm
[2] Danish Patent and Trademark Office. (2022). Patent Law. Retrieved from https://danishpatent.dk/en/patent/highlights/patent-law/
[3] WIPO. (2022). Patent Statistics. World Intellectual Property Organization.
